التفاصيل البيبلوغرافية
| العنوان: |
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study |
| المؤلفون: |
Grünwald, Viktor, Powles, Thomas, Kopyltsov, Evgeny, Kozlov, Vadim, Alonso-Gordoa, Teresa, Eto, Masatoshi, Hutson, Thomas, Motzer, Robert, Winquist, Eric, Maroto, Pablo, Keam, Bhumsuk, Procopio, Giuseppe, Wong, Shirley, Melichar, Bohuslav, Rolland, Frederic, Oya, Mototsugu, Rodriguez-Lopez, Karla, Saito, Kenichi, McKenzie, Jodi, Porta, Camillo |
| المصدر: |
European Urology Oncology; 20230101, Issue: Preprints |
| مستخلص: |
Patients with an early (6-mo) tumor response appeared to have survival benefit versus those without a response (particularly among those receiving lenvatinib plus pembrolizumab). Thus, an early response could be considered when evaluating treatment. |
| قاعدة البيانات: |
Supplemental Index |
